玻璃体内注射曲安奈德治疗Vogt-小柳-原田综合征
Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome.
作者信息
Karacorlu M, Arf Karacorlu S, Ozdemir H
机构信息
Istanbul Retina Institute, Inc., Istanbul, Turkey.
出版信息
Eur J Ophthalmol. 2006 May-Jun;16(3):481-3. doi: 10.1177/112067210601600322.
PURPOSE
To report the results of intravitreal triamcinolone acetonide in two eyes of a patient with Vogt-Koyanagi-Harada syndrome.
METHODS
A 24-year-old woman with Vogt-Koyanagi-Harada syndrome was treated with a single 4-mg dose of intravitreal injection of triamcinolone acetonide in both eyes.
RESULTS
On the seventh day after injection, visual acuity improved from 20/50 to 20/20 in the right eye and from 20/100 to 20/32 in the left. One month after injection, visual acuity was 20/20 in the right eye and 20/32 in the left, and fluorescein angiography showed that serous detachment had almost completely resorbed. The ocular examination remained stable during the 8-month follow-up period.
CONCLUSIONS
In this study, a prompt improvement in the clinical picture of a patient with Vogt-Koyanagi-Harada syndrome after intravitreal triamcinolone acetonide injection was described. The results suggest that intravitreal triamcinolone acetonide injection may be an additional tool in the treatment of Vogt-Koyanagi-Harada syndrome.
目的
报告玻璃体内注射曲安奈德治疗1例Vogt-小柳-原田综合征患者双眼的结果。
方法
1例24岁Vogt-小柳-原田综合征女性患者双眼单次玻璃体内注射4mg曲安奈德。
结果
注射后第7天，右眼视力从20/50提高到20/20，左眼视力从20/100提高到20/32。注射后1个月，右眼视力为20/20，左眼为20/32，荧光素血管造影显示浆液性脱离几乎完全吸收。在8个月的随访期内眼部检查保持稳定。
结论
本研究描述了玻璃体内注射曲安奈德后Vogt-小柳-原田综合征患者临床表现迅速改善的情况。结果表明，玻璃体内注射曲安奈德可能是治疗Vogt-小柳-原田综合征的一种辅助手段。
Zotero 插件